These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29678394)

  • 1. [Dermatologic toxicities of immune checkpoint inhibitors].
    Sibaud V; Boulinguez S; Pagès C; Riffaud L; Lamant L; Chira C; Boyrie S; Vigarios E; Tournier E; Meyer N
    Ann Dermatol Venereol; 2018 May; 145(5):313-330. PubMed ID: 29678394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
    Sibaud V; Meyer N; Lamant L; Vigarios E; Mazieres J; Delord JP
    Curr Opin Oncol; 2016 Jul; 28(4):254-63. PubMed ID: 27136138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
    Zarbo A; Belum VR; Sibaud V; Oudard S; Postow MA; Hsieh JJ; Motzer RJ; Busam KJ; Lacouture ME
    Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
    J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
    Chen WS; Tetzlaff MT; Diwan H; Jahan-Tigh R; Diab A; Nelson K; Glitza IC; Kaunitz GJ; Johnson D; Torres-Cabala C; Pacha O; Taube JM; Maloney K; Prieto VG; Curry JL
    J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
    Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
    Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
    Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune-related adverse events after immune checkpoints inhibitors in 2019: An update].
    Comont T; Belliere J; Sibaud V; Alric L; Meyer N; Mazières J; Caron P; Acket B; Michot JM; Beyne-Rauzy O; Lambotte O
    Rev Med Interne; 2020 Jan; 41(1):37-45. PubMed ID: 31668882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.
    Rambhia PH; Reichert B; Scott JF; Feneran AN; Kazakov JA; Honda K; Koon H; Gerstenblith MR
    Int J Clin Oncol; 2019 Oct; 24(10):1171-1181. PubMed ID: 31321613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.